Hormone Therapy Market to Reach USD 41.97 Billion by 2035, Growing at 7.20% CAGR

The global hormone therapy market size is calculated at USD 22.45 billion in 2026 and is expected to reach around USD 41.97 billion by 2035, growing at a CAGR of 7.20% for the forecasted period.

Ottawa, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The global hormone therapy market size was valued at USD 20.96 billion in 2025 and is predicted to hit around USD 41.97 billion by 2035, rising at a 7.20% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research. This growth is driven by emerging trends and strong demand across key sectors.

The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/6258

Key Takeaways

• North America was dominant in the market in 2024.
• Asia-Pacific is expected to grow at the fastest CAGR during 2025-2034.
• By therapy type, the cancer hormone therapy segment held a major revenue share of the market in 2024.
• By therapy type, the androgen replacement therapy segment is expected to witness rapid expansion in the predicted timeframe.
• By hormone source, the synthetic hormones segment registered dominance in the market in 2024.
• By hormone source, the bioidentical/natural hormones segment is expected to grow fastest in the coming years.
• By route of administration, the oral segment led the global hormone therapy market in 2024.
• By route of administration, the transdermal segment is expected to grow rapidly during 2025-2034.
• By application/indication, the menopause & andropause management segment held the largest revenue share of the market in 2024.
• By application/indication, the oncology segment is expected to register the fastest growth in the studied years.
• By end-user, the hospitals & specialty clinics segment dominated the market in 2024.
• By end-user, the retail & online pharmacies segment is expected to grow at the fastest CAGR during 2025-2034.

Expanding Awareness Regarding Health Issues: How Does It Transform the Global Progression?

Primarily, the hormone therapy market covers the utilisation of hormones in two different conditions, i.e. for blocking the effects of specific hormones or for replacing the missing hormones. These hormones are widely employed in certain cancers (prostate, breast), menopause symptoms, and fibroids. The prominent growth of the market is driven by a rise in the geriatric population, rising awareness related to menopause and thyroid disorders, and breakthroughs in drug delivery methods and new formulations.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

What are the Significant Drivers in the Hormone Therapy Market?

Ongoing developments in the respective market are mainly fueled by the increasing cases of hypothyroidism, growth hormone deficiency, male hypogonadism, and menopause-related concerns, like hot flashes, osteoporosis risk. For these instances, many leading companies are putting efforts into the development of diverse long-acting injectables, transdermal patches, gels, sprays, and subcutaneous implants, which frequently facilitate persistent hormone levels and bypass first-pass liver metabolism.

What are the Key Trends in the Hormone Therapy Market?

• In June 2025, The HRT Club, a major innovator of direct-to-consumer hormone replacement therapies, partnered with Posterity Health to accelerate the development of a strong and inclusive approach to hormonal health.
• In October 2025, Virtual health care provider Elektra Health collaborated with Oscar Health, a health care technology company, to introduce the first menopause-focused health insurance plan in the US.

What is the Developing Challenge in the Hormone Therapy Market?

A substantial limitation is that the growing need for greater spending, especially on new or compounded bioidentical formulations, is a crucial hurdle for numerous patients. Alongside, patients may have critical side effects, such as mood swings, headaches, weight gain, and nausea, which can affect treatment adherence and satisfaction.

Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting

Regional Analysis

How did North America hold a Major Revenue Share of the Market in 2024?

In 2024, North America registered dominance with the biggest share of the hormone therapy market. A combination of factors is impacting the regional expansion, are the presence of a suitable regulatory landscape, a rising number of hormonal imbalance incidences, continuous research and development activities, and novel candidate launches. The latest development includes the FDA-approved elinzanetant as the treatment for moderate to severe vasomotor symptoms (hot flashes) connected with menopause, in October 2025.

Why did the Asia Pacific Expand Notably in the Hormone Therapy Market in 2024?

During 2025-2034, the Asia Pacific is anticipated to expand rapidly in the market. Ongoing progression of various hospitals and retail pharmacies in the ASAP is boosting the availability of hormone therapy treatments. Also, a rise in public and professional awareness of hormonal concerns, mainly menopause-related symptoms and hypothyroidism, is resulting in more diagnoses and treatments. Recently, the Asia-Pacific Menopause Federation (APMF) published the latest consensus statement, facilitating a roadmap for clinicians managing menopause.

Hormone Therapy Market: Revolutionary Efforts in 2024-2025

Medical Research Future Fund (MRFF)	Offered up to $25 million fund for a major opportunity that emphasized perimenopause and menopause research.
Ireland Budget 2025	It announced €20 million full-year cost investment for facilitating state-funded HRT products for women with menopause symptoms.
NIH Research	This continued its research funding on women's midlife health and cardiovascular disease in women through various grants and initiatives, such as the Women's Health Initiative (WHI).

Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Segmental Insights

By therapy type analysis

Which Therapy Type Led the Hormone Therapy Market in 2024?

The cancer hormone therapy segment was dominant with a dominant share of the market in 2024. Due to the increasing prevalence of many cancer types, the globe is shifting towards customized treatment solutions, like HT, which is fueling the segmental growth. Alongside, well-developed firms are fostering the emergence of novel drug classes, such as Selective Estrogen Receptor Degraders (SERDs) and PROTACs, and enhancing outcomes for specific genetic mutations in breast and prostate cancers. 

Whereas the androgen replacement therapy segment will expand rapidly in the coming era. An ageing population are facing the rise in hypogonadism, which is mainly driving the demand for this therapy. Ongoing revolutions, including hormone monitoring technologies, like wearable biosensors and at-home testing kits, are also bolstering the ART treatments. In March 2024, Mangoceuticals Inc. introduced 'PRIME', an oral ART led by the FDA-approved Kyzatrex formulation.

By hormone source analysis

How did the Synthetic Hormones Segment Lead the Market in 2024?

In 2024, the synthetic hormones segment captured the largest share of the hormone therapy market. As the world is stepping towards personalized solutions, and the persistent development in novel delivery systems is increasingly using these hormones. In recent days, the FDA-approved drug DuaVee (conjugated estrogens/bazedoxifene) has been employed in postmenopausal women with a uterus.

On the other hand, the bioidentical/natural hormones segment is predicted to expand at a rapid CAGR. They have tremendous benefits in the growing demand for tailored treatment approaches, as well as consistent developments in novel and optimized delivery methods, like transdermal patches, gels, and creams, with greater convenience and lessen side effects. Numerous women are adopting recently FDA-approved bioidentical hormones, particularly the oral capsule combination of estradiol and micronized progesterone (Bijuva).

By route of administration analysis

What Made the Oral Segment Dominant in the Market in 2024?

The oral segment accounted for the largest share of the hormone therapy market in 2024. Emerging advantages, such as convenience and ease of administration, widespread accessibility of generics, and high patient compliance, are emphasising the demand for this ROA. Currently, many companies are focusing on the transformation of next-generation oral Selective Estrogen Receptor Degraders (SERDs) for estrogen receptor-positive (ER+), human epidermal growth factor 2-negative (HER2-) advanced or metastatic breast cancer.

However, the transdermal segment is estimated to register the fastest growth in the upcoming years. Specifically, it is a non-invasive, convenient, and safe treatment option; also, it can avoid first-pass metabolism, thus broadly used in various cases. Nowadays, researchers are promoting clinical trials with "smart patches" that use biosensors or Bluetooth technology to track hormone absorption in real time and send data to a smartphone. Last year, an example stated that an extended-use patch with a 7-day lifecycle lowered the frequency of changes by 50%.

By application/indication analysis

Which Application/Indication Dominated the Hormone Therapy Market in 2024?

The menopause & andropause management segment registered dominance in the market in 2024. Developing healthcare systems, a rising geriatric population, and growing advancements in hormone therapy technology are assisting HRT application in these cases. The American Urologic Association (AUA) presented 2025 guidelines that ensure the safety and efficacy of low-dose vaginal estrogen and DHEA for genitourinary syndrome of menopause (GSM), like the prevention of recurrent urinary tract infections. 

Although the oncology segment is estimated to grow rapidly. The increasing hormone-dependent cancers, such as breast, prostate, ovarian, and endometrial cancers instances are fueling the wider demand for HRT. An extensive use of triplet therapy (ADT + ARPI + docetaxel chemotherapy) has displayed substantial survival advantages, mainly in patients with high-volume metastatic castration-sensitive prostate cancer (mCSPC). In October 2025, Phase III AMPLITUDE results showed that the PARP inhibitor niraparib, combined with abiraterone acetate and prednisone, combats the growth of advanced prostate cancer.

By end-user analysis

What Made the Hospitals & Specialty Clinics Segment Dominant in the Market in 2024?

The hospitals & specialty clinics segment captured the biggest share of the hormone therapy market in 2024. They significantly offer expert knowledge, more sophisticated diagnostics, personalized care strategies, and a comprehensive, multidisciplinary approach that highlights the broader connected health risks. In July 2025, BC Women's Hospital + Health Centre introduced a new Complex Menopause Clinic in Vancouver, Canada.

However, the retail & online pharmacies segment is predicted to witness rapid expansion. They usually facilitate face-to-face counselling, answer questions, and provide reassurance about treatment options, including Hormone Replacement Therapy (HRT). The wider community pharmacies facilitate health screening services and educational programs that support women in understanding their symptoms and available management choices.

Browse More Insights of Towards Healthcare:

The global steroid hormone API market, valued at US$ 3.54 billion in 2024, is expected to increase to US$ 3.74 billion in 2025 and further reach US$ 6.06 billion by 2034, advancing at a CAGR of 5.54% between 2025 and 2034.

Meanwhile, the human growth hormone injection market is rapidly progressing, with revenue anticipated to scale significantly reaching hundreds of millions of dollars during the 2025–2034 period.

The global cancer supportive care drugs market stands at US$ 21.89 billion in 2024, rising to US$ 22.36 billion in 2025, and is projected to reach US$ 27.05 billion by 2034, driven by a 2.14% CAGR over the forecast timeline.

Similarly, the global cancer diagnostics market, valued at USD 109.65 billion in 2024, is set to grow to USD 116.42 billion in 2025, and is expected to reach USD 199.54 billion by 2034, expanding at a 6.17% CAGR from 2025 to 2034.

The cancer vaccines market is forecasted to surge from USD 11.38 billion in 2025 to USD 33.61 billion by 2034, marking an impressive 11.44% CAGR during the assessment period.

In the broader therapeutic landscape, the global oncology drugs market estimated at US$ 204.39 billion in 2024 is projected to grow to US$ 217.18 billion in 2025, ultimately reaching US$ 360.79 billion by 2034, registering a 6.29% CAGR throughout 2025–2034.

The global oncology API market follows a similar upward trajectory, valued at USD 41.79 billion in 2024, increasing to USD 43.95 billion in 2025, and expected to reach USD 69.55 billion by 2034, at a steady 5.24% CAGR over the forecast period.

The oncology drug discovery market is also set for robust growth between 2024 and 2034, propelled by advancements in precision medicine, AI-powered drug development, and an expanding pipeline of targeted therapies.

Additionally, the global oncology clinical trials market is projected to rise from US$ 13.64 billion in 2024 to US$ 14.36 billion in 2025, and further escalate to US$ 22.85 billion by 2034, advancing at a 5.30% CAGR.

One of the fastest-growing segments, the global oncology biosimilars market, is valued at US$ 6.7 billion in 2024, expected to grow to US$ 7.94 billion in 2025, and projected to reach US$ 36.23 billion by 2034, reflecting a remarkable 18.47% CAGR during 2025–2034.

What are the Major Developments in the Hormone Therapy Market?

• In October 2025, Tia, a major provider of whole-person women’s healthcare, launched its Hormone & Vitality Assessment, a first-of-its-kind assessment created for women addressing changes in their bodies, from sleep and mood shifts to energy and weight. 
• In November 2025, Miami's Amavita Heart & Vascular Health unveiled cardiologist-led testosterone therapy, setting a new standard for men's cardiovascular safety.
• In August 2025, SynergenX, a national company personalized hormone optimization, expanded its hormone replacement therapy (HRT) services for women to include injections of testosterone cypionate.
  

Hormone Therapy Market Key Players List

• Pfizer
• Elli Lilly
• Novartis
• Merck KGaA
• Novo Nordisk A/S
• Ipsen Pharma
• Ferring Pharmaceuticals
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (Viatris Inc.)
• Sun Pharmaceutical Industries Ltd.
• Cipla Ltd.
• Dr. Reddy’s Laboratories Ltd.
• Ascendis Pharma A/S
  

Segments Covered in the Report

By Therapy Type

• Cancer Hormone Therapy
  • Prostate Cancer
    • Anti-Androgens
  • Breast Cancer
    • SERMs
    • Aromatase Inhibitors
    • LHRH Agonists/Antagonists
• Androgen Replacement Therapy (Testosterone, DHEA)
• Menopausal Hormone Therapy (Estrogen, Progesterone, Combination Therapy)
• Thyroid Hormone Therapy (Levothyroxine, Liothyronine, Combination Therapy)
• Growth Hormone Therapy (Somatropin, IGF-1 Analogues)
• Gender-Affirming Hormone Therapy
  • Transgender Care
    • Estrogen
    • Anti-Androgens
    • Testosterone

By Hormone Source

• Synthetic Hormones
• Bioidentical/Natural Hormones
• By Route of Administration
• Oral (Pills, Capsules, Tablets)
• Transdermal (Patches, Gels, Creams, Sprays)
• Injectable (Intramuscular, Subcutaneous)
• Implants & Pellets
• Others (Nasal Sprays, Vaginal Rings, Inhalation)

By Application/Indication

• Menopause & Andropause Management
• Oncology (Breast Cancer, Prostate Cancer, Endometrial Cancer, Others)
• Hypothyroidism & Hyperthyroidism
• Growth Disorders in Children & Adults
• Gender-Affirming Care (Transgender Hormone Therapy)
• Osteoporosis Prevention & Bone Health

By End-User

• Hospitals & Specialty Clinics
• Retail & Online Pharmacies
• Research & Academic Institutions
  

By Region 

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/6258

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard: https://www.towardshealthcare.com/access-dashboard

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web: https://www.towardshealthcare.com

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.